Crescent Biopharma, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-33.3M | $-31.8M | $-12.8M | $-11.1M | $-10.6M | $3.7M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $263.5K | $190.5K | $191.5K | $158.7K | $133.1K | $99.9K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $3.8M | $3.0M | $2.3M | $1.6M | — | — |
| Net Cash from Operating Activities | $-29.8M | $-29.7M | $-8.2M | $-4.3M | $-15.5M | $-10.5M |
| Investing Activities | ||||||
| Capital Expenditures | $294.1K | $704.2K | $268.6K | $212.6K | $82.1K | $316.2K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-294.1K | $-704.2K | $-268.6K | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $113.9M | $23.7M | $114.1K | — | — | — |
| Net Change in Cash | $83.9M | $-6.8M | $-8.4M | $52.9M | $-15.1M | $-10.8M |
| Free Cash Flow | $-30.1M | $-30.4M | $-8.5M | $-4.5M | $-15.6M | $-10.8M |